Inactive Instrument

Press Releases Kadmon Holdings, Inc.

Equities

KDMN

US48283N1063

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sanofi completes acquisition of Kadmon - Form 8-K	21-11-09	PU
KADMON HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendme (form 8-K)	21-11-09	AQ
KADMON HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	21-11-05	AQ
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results	21-11-04	PU
KADMON HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-11-04	AQ
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results - Form 8-K	21-11-04	PU
KADMON HOLDINGS, INC. : Other Events (form 8-K)	21-10-28	AQ
KADMON HOLDINGS, INC. : Other Events (form 8-K)	21-10-21	AQ
Kadmon : Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting	21-10-01	PU
KADMON HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN	21-09-10	BU
Sherwin Williams : PulteGroup fall; Perrigo, Kadmon rise	21-09-08	AQ
Kadmon : Sanofi to acquire Kadmon to further strengthen growth of transplant business (Form 8-K)	21-09-08	PU
KADMON HOLDINGS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	21-09-08	AQ
Kadmon : Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)	21-08-19	PU
KADMON : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-08-05	AQ
Kadmon : Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation	21-08-04	PU
Kadmon : Corporate Presentation	21-07-27	PU
Kadmon : REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy (Form 8-K)	21-07-19	PU
KADMON HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	21-07-19	AQ
Kadmon : Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD)	21-07-19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kadmon Holdings, Inc.

Equities

KDMN

US48283N1063

Press Releases

Filters